Core Insights - Moderna's seasonal influenza vaccine candidate, mRNA-1010, demonstrated superior relative vaccine efficacy compared to GSK's flu shot in a phase III study involving adults aged 50 and above [1][2][8] Efficacy Results - mRNA-1010 achieved a relative vaccine efficacy (rVE) that was 26.6% higher than GSK's flu shot, based on a study population of over 40,000 participants across 11 countries [2][8] - The vaccine showed strong efficacy against key influenza strains: 29.6% for A/H1N1, 22.2% for A/H3N2, and 29.1% for the B/Victoria lineage [3] - In participants aged 65 and older, mRNA-1010 achieved an rVE of 27.4%, indicating consistent benefits across age groups and previous vaccination status [3][8] Study Consistency - The results from the P304 study align with previous phase III immunogenicity study (P303), which indicated that mRNA-1010 generated immune responses comparable to existing standard and high-dose flu vaccines [4] Regulatory Plans - Moderna plans to discuss the study results with the FDA and other global regulators for potential regulatory submissions regarding mRNA-1010 [5][8] Stock Performance - Following the announcement of the study results, Moderna's shares rose nearly 2%, reflecting improved prospects for the approval of a standalone flu vaccine [6][8] - Year-to-date, Moderna's stock has decreased by 34%, contrasting with a 4% decline in the industry [7] Recent Challenges - In May, the U.S. government terminated contracts worth $766 million for the development of an mRNA-based bird flu vaccine, impacting Moderna's funding and operational strategy [11] - New FDA guidelines for COVID-19 vaccine boosters may reduce demand for Moderna's products, particularly among healthy individuals under 65 [12]